The New York Pharma Forum 25th Annual General Assembly: "The Future of Aging"
December 5, 2014 - New York NY USThe New York Pharma Forum
cgano@bridgeny.com
Phone:212-583-1043 EXT 14
The 25th Anniversary New York Pharma Forum General Assembly will be held on December 5, 2014, from 3:00-5:30 PM at the New York Athletic Club. Note: Due to the New York Athletic Club Dress Code, jackets are required for gentlemen and comparable attire for ladies. Topic: “The Future of Aging” New York Pharma Forum’s 25th General Assembly will address the challenges of aging populations and of aging itself, with an emphasis on new ideas and work underway to improve longevity and quality of life for the elderly. In addition to covering the medical and pharmaceutical industry outlook for aging, experts will discuss the social, psychological and financial impacts of aging, and the future outlook for aging at both the individual and societal levels. Moderator for the program will be Yuji Matsue, Senior Vice President, Eisai Co., Ltd.; Chairman & CEO, Eisai Inc. Mr. Matsue is chair for this year’s 25th Anniversary New York Pharma Forum General Assembly. He returned to the U.S. from Eisai Co., Ltd.’s Tokyo headquarters in April 2014 to head Eisai’s Americas Region. Prior to his current position, which is based at Eisai Inc.’s Woodcliff Lake, New Jersey headquarters, Mr. Matsue held several key senior management positions at Eisai in Japan, Europe and the United States. His previous position was as Deputy President for the Asia Region at Eisai Co., Ltd., based in Tokyo. This is Mr. Matsue’s second U.S. assignment for Eisai. He came to the U.S. in 1995 to become one of Eisai Inc.’s first five employees, working as a member of the launch team for Aricept, Eisai’s drug for Alzheimer’s disease, which was the company’s first U.S. product. Speakers: Laura Deming Partner, The Longevity Fund The Longevity Fund is a specialty life science venture capital firm focused on pharmaceutical companies developing therapies for aging-associated pathology. The fund backs companies with early stage therapies that target the aging process to treat late-onset medical conditions. Ms. Deming says that when she was a young child, she realized that we were all going to die of a disease called aging; and ever since, her driving passion has been to slow aging and eliminate age-related diseases. She started working in a biogerontology lab when she was 12 years old, and enrolled at MIT at age 14. At 17, she was one of the youngest “20under20” fellows awarded a grant by Peter Thiel (venture capitalist and hedge fund manager who co-founded PayPal). Ms. Deming will discuss the business and financial challenges of fighting age-related diseases, including the prospect for venture-funding in this area. Dallas Salisbury President and CEO, Employee Benefits Research Institute (EBRI) EBRI is a Washington-based non-profit that conducts research on retirement plans and other employee benefits. EBRI provides objective research, data, education and insight to inform decision-making. Mr. Salisbury has been with EBRI since its founding in 1978. His assignments with advisory groups and boards have included Social Security Administration Appointee to the Outside Scholar Panels for its Financial Literacy Research Consortium; the Securities and Exchange Commission Investor Advisory Committee; the Board of Advisors to the Comptroller General of the United States; Boards of Directors of the FINRA Investor Education Foundation, the Secretary of Labor’s ERISA Advisory Council; the presidentially-appointed Pension Benefit Guarantee Corporation Advisory Committee; member of the Bipartisan Policy Center Commission on Retirement Security and Personal Savings; and numerous others. Mr. Salisbury will discuss the challenges of funding retirement for today’s aging population, and the future he predicts for pension funds and retirement incomes. Rachel Schindler, M.D. Clinical Disease Area Expert, Alzheimer’s Disease, Vice President, Clinical Sciences, Pfizer Inc. Dr. Schindler is Pfizer’s category expert on Alzheimer’s. She is frequently interviewed by the media on AD. Dr. Schindler is a neurologist with extensive academic, clinical and pharmaceutical experience across neurological and psychiatric disorders, with subspecialty expertise in Alzheimer’s disease and other neurocognitive and neuropsychiatric disorders. She’s an internationally-recognized leader in AD with broad experience lecturing, participating in and leading expert panels and consensus groups, as well as teaching. She has experience in a broad range of, and across all aspects of, clinical trials in Neurology and Psychiatry, including as a principal investigator in the Alzheimer’s Disease Cooperative. At Pfizer, she has held a series of positions in both Medical Affairs and Clinical Development in the post-proof of concept space, working globally and across regions. Dr. Schindler will focus on the Alzheimer’s pipeline and on promising research to battle this disease in the future. Ursula M. Staudinger, Ph.D. Founding Director, Robert N. Butler Columbia Aging Center, Mailman School of Public Health, Columbia University The Center, established in 2013, is a global hub for interdisciplinary aging research and knowledge transfer to policy makers, companies and the general public. Dr. Staudinger also heads the International Longevity Center USA, founded by Dr. Robert N. Butler and now part of the Columbia Aging Center. Dr. Staudinger’s previous positions included Vice President of Jacobs University Bremen in Germany and Founding Dean of its Jacobs Center on Lifelong Learning and Institutional Development; Professor of Developmental Psychology at the Technical University Dresden; and Senior Scientist at the Max Planck Institute of Human Development in Berlin. Her research focuses on opportunities and challenges of increases in average life expectancy. She will discuss the social underpinnings, policies and structures that must change to facilitate healthy, productive aging, including patterns of working, learning, such as workforce development, civic engagement, human resource allocation and urban design. Toshihiko Takeda, Deputy Director-General of the Health Insurance Bureau; Ministry of Health, Labour & Welfare; Government of Japan A graduate of Tokyo University, Mr. Takeda has spent his entire career working in the government, chiefly in the health ministry. From 1990-1993 he was assigned by his ministry to serve in New York as Director of Health & Welfare at the Japan External Trade Organization (JETRO-New York). He served as an advisor to the Board of Directors of New York Pharma Forum at that time, in its formative years. Mr. Takeda has served in numerous health, medical and pharmaceutical positions within his ministry and has also been assigned to temporary positions in other Japanese government organizations, such as, most recently, the Fire and Disaster Management Agency of the Ministry of Internal Affairs & Communications. He will speak about the big challenges presented by the aging of Japan’s population, which is aging faster than any other country in the world, and about measures the Japanese government is taking to help meet those challenges. [Mr. Takeda is speaking in place of Shiro Yamasaki, included in the original announcement for this event, but whose government responsibilities kept him from coming to New York.]